Pfizer Corporation

Michelle Renee Garnsey

David Andrew Griffith

Travis T Wager

Jaclyn Louise Henderson

Bethany Lyn Kormos

Martin Youngjin Pettersson

Antonia Friederike Stepan

Paul Galatsis

Ravi G Kurumbail

Patrick Robert Verhoest

Christopher Ryan Butler

Christopher John Helal

Kentaro Futatsugi

Thomas Allen Chappie

Kevin James Filipski

David James Edmonds

Aaron Smith

Matthew Forrest Sammons

Matthew Richard Reese

Karen Jean Coffman

Qingyi Yang

Jana Polivkova

Daniel Jonathan Smaltz

Luis Angel Martinez-Alsina

Kevin Alexander Ogilvie

Jack Chang Hung Lee

Michael Aaron Brodney

Jotham Wadsworth Coe

Joseph Scott Warmus

Yuan Zhang

Brian Kenneth Raymer

Daniel Wei-Shung Kung

Jinshan Michael Chen

Yajing Lian

Colin Richard Rose

Aaron Christopher Smith

Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I:

Methods for antagonizing a melanocortin 4 receptor

Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R, R, R, X, Y, Y, Y, Yand Yare defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.

Melanocortin 4 receptor antagonists and uses thereof

Described herein are compounds of Formula (I) wherein R, R, R, R, R, R, R, Rand Rare defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.

Diacylglycerol acyl transferase 2 inhibitor

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Cyclic substituted imidazo[4,5-c]quinoline derivatives

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R, R, R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors

Growing community of inventors

Providence, RI, United States of America

Michelle Renee Garnsey